Triptorelin dosing — clinician-administered depot

Triptorelin is a GnRH agonist used, for example, in advanced prostate cancer and other hormone-driven conditions. Its defining feature is that it is delivered as a long-acting depot administered by a clinician — it is not a vial someone reconstitutes and injects at home.

The approved products are depot formulations dosed on a clinic schedule rather than daily:

• A depot injection given by a clinician, chosen by formulation strength.
• Common intervals are monthly, every three months, or every six months, depending on the specific product.
• Each depot slowly releases drug over its whole interval, so a single administration covers weeks to months.

Because the interval is built into the formulation, this is not a "start low and titrate weekly" schedule — the clinician selects the appropriate depot and re-administers on its interval.

The body normally releases GnRH in pulses. Delivered continuously as a depot, triptorelin first causes a brief flare and then desensitizes the pituitary, which suppresses downstream sex hormones. That sustained, plateau-like exposure is exactly what the depot format is designed to produce — and why a depot, not a daily shot, is used.

The depot is prepared and injected by a healthcare professional (intramuscular or subcutaneous depending on the product) in a clinical setting.

• The approved product is supplied as a defined depot kit, so the amount is fixed and verified.
• Because it is clinician-administered on a schedule, there is no at-home reconstitution or unit-reading step for the patient.

Triptorelin causes an initial testosterone/estrogen surge before suppression, which must be managed clinically, and it has indication-specific contraindications and monitoring. A treating clinician selects the depot, times each administration, and watches response and side effects. This is a prescription therapy directed by a professional, not a self-administered protocol.